Spectrum Pharmaceuticals Inc.
06/02/2021 | Press release | Distributed by Public on 06/02/2021 14:26
Letter from Deloitte & Touche LLP addressed to the Securities Exchange Commission, dated June 2, 2021 (Form 8-K)
June 2, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Spectrum Pharmaceuticals, Inc.'s Form 8-K dated June 2, 2021, and have the following comments:
1. We agree with the statements made in the second, third, and fourth paragraphs of 4.01(a).
2. We have no basis on which to agree or disagree with the statements made in the first paragraph of 4.01(a), and 4.01(b).
Yours truly,
/s/ Deloitte & Touche LLP